MX2020003549A - Fusiones de transtiretina e inmunoglobulina. - Google Patents

Fusiones de transtiretina e inmunoglobulina.

Info

Publication number
MX2020003549A
MX2020003549A MX2020003549A MX2020003549A MX2020003549A MX 2020003549 A MX2020003549 A MX 2020003549A MX 2020003549 A MX2020003549 A MX 2020003549A MX 2020003549 A MX2020003549 A MX 2020003549A MX 2020003549 A MX2020003549 A MX 2020003549A
Authority
MX
Mexico
Prior art keywords
transthyretin
immunoglobulin fusions
ttr
fusion proteins
present
Prior art date
Application number
MX2020003549A
Other languages
English (en)
Inventor
Kenneth Walker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2020003549A publication Critical patent/MX2020003549A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a fusiones con transtiretina (TTR) útiles en la dimerización y tetramerización de anticuerpos y fragmentos de anticuerpos, tales como Fab. Las proteínas de fusión con TTR son particularmente útiles para aumentar la avidez del anticuerpo y para potenciar el agrupamiento de antígeno. En el presente documento se describen métodos para tratar enfermedades usando las proteínas de fusión de la presente invención.
MX2020003549A 2017-10-04 2018-10-03 Fusiones de transtiretina e inmunoglobulina. MX2020003549A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762568217P 2017-10-04 2017-10-04
PCT/US2018/054237 WO2019070901A1 (en) 2017-10-04 2018-10-03 IMMUNOGLOBULIN FUSIONS OF TRANSTHYRETIN

Publications (1)

Publication Number Publication Date
MX2020003549A true MX2020003549A (es) 2020-08-03

Family

ID=64110020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003549A MX2020003549A (es) 2017-10-04 2018-10-03 Fusiones de transtiretina e inmunoglobulina.

Country Status (11)

Country Link
US (1) US12269898B2 (es)
EP (1) EP3692061A1 (es)
JP (3) JP2020537506A (es)
CN (1) CN111164101B (es)
AU (1) AU2018346151B2 (es)
CA (1) CA3076630A1 (es)
EA (1) EA202090581A1 (es)
MA (1) MA50619A (es)
MX (1) MX2020003549A (es)
SG (1) SG11202003114UA (es)
WO (1) WO2019070901A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3692061A1 (en) 2017-10-04 2020-08-12 Amgen Inc. Transthyretin immunoglobulin fusions
EP3997112A1 (en) * 2019-07-08 2022-05-18 Amgen, Inc Multispecific transthyretin immunoglobulin fusions

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2005056605A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
GB0601513D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
CA2815181C (en) 2010-10-27 2020-09-15 William Gleason Richards Dkk1 antibodies and methods of use
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CA2906737C (en) * 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
CA2915386A1 (en) 2013-06-26 2014-12-31 Amgen Inc. Cb1 receptor antigen-binding proteins and uses thereof
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US10421802B2 (en) * 2013-10-18 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
KR20250057056A (ko) 2013-12-20 2025-04-28 뉴리뮨 홀딩 아게 트랜스티레틴(ttr) 아밀로이드증의 항체-기반의 치료 및 이를 위한 인간-유래의 항체
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
RU2017129236A (ru) 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
CN106977609B (zh) * 2017-04-19 2020-07-28 刘崇东 一种融合蛋白、制备方法及其应用
EP3692061A1 (en) 2017-10-04 2020-08-12 Amgen Inc. Transthyretin immunoglobulin fusions
EP3997112A1 (en) 2019-07-08 2022-05-18 Amgen, Inc Multispecific transthyretin immunoglobulin fusions

Also Published As

Publication number Publication date
CN111164101A (zh) 2020-05-15
KR20200059281A (ko) 2020-05-28
AU2018346151A1 (en) 2020-04-02
JP2026035627A (ja) 2026-03-04
US20200317795A1 (en) 2020-10-08
EP3692061A1 (en) 2020-08-12
JP2020537506A (ja) 2020-12-24
WO2019070901A1 (en) 2019-04-11
CA3076630A1 (en) 2019-04-11
CN111164101B (zh) 2025-04-25
US12269898B2 (en) 2025-04-08
JP2024012336A (ja) 2024-01-30
SG11202003114UA (en) 2020-05-28
MA50619A (fr) 2020-08-12
EA202090581A1 (ru) 2020-08-31
AU2018346151B2 (en) 2025-07-03
JP7834075B2 (ja) 2026-03-23

Similar Documents

Publication Publication Date Title
CO2021007956A2 (es) Anticuerpo humanizado anti-pd-1 humana
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CL2023002597A1 (es) Proteínas de unión al antígeno bispecífico de anti-tl1a/anti-tnf-alfa
MX2017002230A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
PE20190737A1 (es) Anticuerpos anti-cd27
CO2019003945A2 (es) Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15rα y fragmentos de anticuerpo pd-1
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
MX360746B (es) Anticuerpos que comprenden dominios constantes quiméricos.
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
BR112022009273A2 (pt) Imunoglobulinas modificadas para direcionar depósitos amiloides
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
UY36302A (es) Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
CY1125561T1 (el) Εξανθρωπισμενα αντισωματα anti-clever-1 και χρηση αυτων
MX351127B (es) Proteínas de unión al antígeno del receptor de oncostatina m.
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EP4495142A3 (en) Bispecific antigen binding construct
CO2020004200A2 (es) Anticuerpo monoclonal anti-il-5rα
MX2020003549A (es) Fusiones de transtiretina e inmunoglobulina.
MX2015009819A (es) Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.
AR099604A1 (es) Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso
EP3613766A4 (en) ENHANCED POLYPEPTIDE IN TERMS OF PROTEIN PURITY AND AFFINITY FOR THE ANTIGEN, ITS CONJUGATE WITH AN ANTIBODY OR FRAGMENT OF IT BOUNDING TO THE ANTIGEN, AND ITS PREPARATION PROCESS